Consensus statement on metabolic disorders and cardiovascular risks in patients with human immunodeficiency virus

Rosa Polo Rodríguez, María José Galindo Puerto, Carlos Dueñas, Carmen Gómez Candela, Vicente Estrada, Noemí G.P. Villar, Jaime Locutura, Ana Mariño, Javier Pascua, Rosario Palacios, Miguel Ángel Von Wichmman, Julia Álvarez, Victor Asensi, José Lopez Aldeguer, Fernando Lozano, Eugenia Negredo, Enrique Ortega, Enric Pedrol, Félix Gutiérrez, Jesús Sanz SanzEsteban Martínez Chamorro

Research output: Contribution to journalArticleResearchpeer-review

7 Citations (Scopus)

Abstract

© 2014 Elsevier España, S.L.U. and Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica. All rights reserved. Objective: This consensus document is an update of metabolic disorders and cardiovascular risk (CVR) guidelines for HIV-infected patients. Methods: This document has been approved by an expert panel of GEAM, SPNS and GESIDA after reviewing the results of efficacy and safety of clinical trials, cohort and pharmacokinetic studies published in biomedical journals (PubMed and Embase) or presented in medical scientific meetings. Recommendation strength and the evidence in which they are supported are based on the GRADE system. Results: A healthy lifestyle is recommended, no smoking and at least 30 min of aerobic exercise daily. In diabetic patients the same treatment as non-HIV infected patients is recommended. HIV patients with dyslipidemia should be considered as high CVR, thus its therapeutic objective is an LDL less than 100 mg/dL. The antihypertensive of ACE inhibitors and ARA II families are better tolerated and have a lower risk of interactions. In HIV-patients with diabetes or metabolic syndrome and elevated transaminases with no defined etiology, the recommended is to rule out a hepatic steatosis Recommendations for action in hormone alterations are also updated. Conclusions: These new guidelines update previous recommendations regarding all those metabolic disorders involved in CVR. Hormone changes and their management and the impact of metabolic disorders onthe liver are also included.
Original languageEnglish
Pages (from-to)40.e1-40.e16
JournalEnfermedades Infecciosas y Microbiologia Clinica
Volume33
Issue number1
DOIs
Publication statusPublished - 1 Jan 2015

Keywords

  • Cardiovascular risk
  • Human immunodeficiency virus infection
  • Metabolic disorders

Fingerprint Dive into the research topics of 'Consensus statement on metabolic disorders and cardiovascular risks in patients with human immunodeficiency virus'. Together they form a unique fingerprint.

Cite this